{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-22-000009","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.986815+00:00","generated_at":"2026-06-22T02:14:14.694530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering","bullets":["Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).","Cash at Sept 30: $50.7M; post-spin-off and $301.9M public offering, pro-forma cash ~$541M with no debt.","Spin-off from Pfizer completed Oct 3, 2022; BHVN began trading independently with $257.8M cash.","Closed public offering of 28.75M shares at $10.50/share, gross proceeds $301.9M (net $282.8M).","Pipeline milestones: BHV-7000 Phase 1 complete H1 2023; troriluzole Phase 3 OCD enrollment in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-22-000009","json":"https://secwatch.observer/filing/0001935979-22-000009.json","markdown":"https://secwatch.observer/filing/0001935979-22-000009.md","text":"https://secwatch.observer/filing/0001935979-22-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/0001935979-22-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/bhvn-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:14:14.694530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"839a17024037d91f8d64a5736d27084cfbbeb877","claim":"Biohaven Ltd. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"issued a press release announcing its financial results for the third quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/0001935979-22-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}